Advances in the treatment of breast cancer.
Breast cancer is the most commonly diagnosed cancer in American women and is the second leading cause of cancer-related deaths in this population. This review highlights how the use of a multidisciplinary approach to the management of diseases of the breast and the introduction of novel systemic therapies have improved the quality of life and survival in patients with breast cancer.
Moulder
S
S
Department of Breast Medical Oncology and Phase I Program, The University of Texas M. D. Anderson Cancer Center, Houston, Texas, USA. smoulder@mdanderson.org
Hortobagyi
G N
GN
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000188:drug therapy / Q000556:secondary; D001943:Breast Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D017024:Chemotherapy, Adjuvant; D004164:Diphosphonates / Q000627:therapeutic use; D066246:ErbB Receptors / Q000037:antagonists & inhibitors / Q000378:metabolism; D005260:Female; D006801:Humans; D020360:Neoadjuvant Therapy; D010348:Patient Care Team; D018579:Patient Selection; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D011788:Quality of Life; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors / Q000378:metabolism; D035703:Therapies, Investigational; D016896:Treatment Outcome; D014481:United States
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D004164:Diphosphonates; D047428:Protein Kinase Inhibitors; D066246:ErbB Receptors; D040262:Receptors, Vascular Endothelial Growth Factor